Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q1 2024 · 10-Q
Revenue$15.62M$15.62M−18.4% vs Q1 2023 Net Income-$63.33M-$63.33MN/M vs Q1 2023 EPS Diluted-$1.38-$1.38N/M vs Q1 2023 Operating Income-$63,863,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Free Cash Flowderived-$56,012,000N/M Margins · derivedOperating margin-408.8%−63.1 pt vs Q1 2023
Net margin-405.4%−57.0 pt vs Q1 2023
ended Mar 31, 2024 · filed May 8, 2024 · 38 d after period end